{"resource":"https://api.magentlab.com/api/calc/hfa_icos_bcr_abl","service":"magent","areas":["other"],"answering":true,"http_status":402,"latency_ms":208,"price_usdc":0.005,"buyers_30d":1,"calls_30d":2,"description":"Lyon 2020 HFA-ICOS baseline cardiovascular risk before second- or third-generation multi-targeted kinase inhibitors for CML targeting BCR-ABL. Class is very_high, high, medium, or low from published very-high and high factors plus Medium 1/","id":"d9fd4de3416c","category":"Calculators and conversions","accuracy":null,"tool_calls":null,"checked_day":"2026-10-11","page":"https://velliumandco.com/sellers/d9fd4de3416c"}